A continuing medical education session at the Society of Gynecologic Oncology’s 2018 Annual Meeting on Women’s Cancer offered insight for optimal selection and administration of PARP inhibitors, as well as homologous recombination deficiency testing in ovarian cancer. READ MORE

News

The length of time between the end of adjuvant platinum-based therapy and the recurrence of cancer is a strong predictor of survival in older women with recurrent ovarian cancer.

READ MORE

A recent survey asked patients with primary and recurrent ovarian cancer to consider their reasons for choosing maintenance therapy following surgery and chemotherapy.

READ MORE